8-K current report · filed Nov 9, 2026

Cullinan Therapeutics, Inc. (CGEM) 8-K Current Report: November 9, 2026

Item 7.01Item 8.01Item EX-99.1CGEM overview

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE.

Cullinan Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE
  • Velinotamig represents a globally licensed, all-indication asset outside Greater China
  • Data may materially influence velinotamig’s development strategy and valuation, with full results in Exhibit 99.1

Item 8.01 · Other Events

  • Interim Phase 1b/2a data for velinotamig in refractory SLE, with 12 patients treated across three multi-dose cohorts
  • Favorable safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS
  • Eight of nine evaluable patients achieved at least a four-point SLEDAI-2K reduction after four weeks
  • Five of seven patients with baseline proteinuria above 500 mg/24 hours had rapid reductions, including four complete renal responses within 24 weeks
  • Early efficacy supports continued development, but limited sample size and interim data leave durability and regulatory potential unproven

Item EX-99.1 · Exhibit EX-99.1

  • Interim Phase 1b/2a data support velinotamig’s autoimmune proof of concept, with meaningful disease improvement in 8 of 9 evaluable SLE patients
  • Renal signal particularly strong: 4 of 7 patients with baseline proteinuria achieved complete renal responses within 24 weeks
  • Favorable early safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS among 12 treated patients
  • Serologic and pharmacodynamic effects included reduced anti-dsDNA antibodies, IgG, and CD19-positive B cells, supporting plasma-cell targeting
  • Small, early dataset remains nonconfirmatory, but strengthens Cullinan’s broader BCMA strategy and autoimmune cytopenia development plans

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cullinan Therapeutics, Inc. 8-K filings

Get the next CGEM 8-K as it lands

Follow CGEM for push alerts, or ask the research agent what this filing means.